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α-Fetoprotein-producing gastric cancer (AFPGC) is a rare type of gastric cancer. The largest population of patients
with AFPGC is found in China. In the present study, a total of 4,779 GC patients, including 317 AFPGC patients, from
11 clinical studies in China with a general AFPGC/GC ratio of 6.63% were summarized and analyzed. On the basis of
analysis of the clinical data, the patients with AFPGC had larger tumor size, weaker cell differentiation, worse
histopathological types, deeper serosal infiltration, more lymph node and liver metastases, poorer stages, shorter
survival time and more positive expression of vascular endothelial growth factors than the patients without AFPGC.
Our observation is consistent with previous results reported in studies of AFPGC. Overall, AFPGC is a subtype of GC
with a poor prognosis.
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α-Fetoprotein (AFP), initially identified from human fetal
tissue, is normally produced in some fetal organs, pro-
liferating hepatocytes and some adult cancer cells,
including hepatocellular carcinoma cells and yolk sac
tumor cells [1]. However, serum AFP levels sometimes
are elevated in patients with primary gastric cancer (GC)
as well [2]. The GC with a high level of AFP is termed
α-fetoprotein-producing gastric cancer (AFPGC).
The first case of AFPGC was reported by Bourreille et al.
[3]. AFPGC comprises 2.7% to 8.0% of all GCs [4]. In
the past several decades, scientists have given increasing
attention to AFPGC, but to date there still have been
only a few clinical studies with small sample sizes and
sporadic cases of AFPGC. Most of these studies and
cases were reported by Japanese physicians. Most cases
were characterized by a high rate of metastasis to the
liver and lymph nodes. AFPGC is known to frequently
cause multiple liver metastases and to carry an ex-
tremely poor prognosis [5-7]. However, there is still no* Correspondence: wcpjjt@163.com; jjtnew@163.com
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reproduction in any medium, provided the orstandardized process for the treatment of patients with
AFPGC.
China has the largest population of patients with GC,
which implies that the majority of patients with AFPGC
are Chinese. Thus, it is necessary and valuable to pay
attention to clinical observations of AFPGC. Unfor-
tunately, AFPGC studies are still limited, and most of
these studies are case reports. There are few reports
concerning the clinicopathology or prognosis of AFPGC.
Additionally, there is still no published systematic review
or meta-analysis.
On the basis of the considerations mentioned above,
we collected the data of clinical studies of AFPGC in
China with the purpose of providing an overview of
the epidemiology, pathology and clinical prognosis of
AFPGC.Data collection
We chose the VIP database of Chinese scientific and
technological journals (http://en.cqvip.com/), the largest
comprehensive literature database in China, to search the
literature. We entered the keywords “AFPGC” or “jia tai
dan bai AND wei ai” (the equivalent Chinese phrases for
α-fetoprotein AND gastric cancer using Chinese charac-
ters) and searched for clinical studies in which patients
with AFP-positive GC were examined. We have com-
pleted the preliminary screening and obtained 55 articles.his is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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controlled studies and five noncontrolled retrospective
studies. These studies were published in the following
medical journals with the ISSNs and number of studies
from each: Chinese Journal of Current Advances in
General Surgery (ISSN 1009–9905; n = 1), Journal of
Modern Oncology (ISSN 1672–4992; n = 1), Zhejiang
Medical Journal (ISSN 1006–2785; n = 1), Journal of
Chinese Physician (ISSN 1006–2440; n = 1), Medical
Journal of Communications (ISSN 1006–2440; n = 2),
Jiangxi Medical Journal (ISSN 1006–2238; n = 1), Journal
of Clinical & Experimental Pathology (ISSN 2161–0681;
n = 1), Modern Journal of Integrated Traditional Chinese
and Western Medicine (ISSN 1008–8849; n = 1), Journal
of Practical Oncology (ISSN 1001–1692; n = 1) and
Chinese Clinical Oncology (ISSN 2304–3873; n = 1).
These studies are published in Chinese, but the abstracts
of these articles are in both Chinese and English. The
studies that were published in English in Chinese journals
were excluded. The following 11 articles were included
(studies 1 through 6 were randomized controlled studies,
and studies 7 through 11 were noncontrolled retrospective
studies):
1. Tian L, Yao K, Wu A, Li L, Zhang Z, Pei, T, Liu L:
Retrospective analysis of 32 α-fetoprotein
producing gastric cancer cases. Chin J Curr Adv
Gen Surg 2011, 14:441–453.
2. Mi H, Zhao X, Yang Y: Expression of AFP in gastric
carcinoma and its relationship with VEGF. Mod
Oncol 2011, 19:106–108.
3. Wang F, Zheng Z: The clinicopathological features
of α-fetoprotein positive gastric cancer.
Zhejiang Med J 2004, 26:895–896.
4. Li B, Luo J, Li J: Clinical significance of
α-fetoprotein (AFP) expression in gastric carcinoma
patients. J Chin Physician 2007, 9:606–607.
5. Shi Y, Chou A, Wang X: Clinical significance of
α-fetoprotein in gastric carcinoma patients. Med J
Commun 2006, 20:698–700.
6. Peng Z, Xiong J: The analysis of the relationship
between serum AFP and the clinicopathology of the
stomach. Jiangxi Med J 2009, 44:301–304.
7. Li X, Shi F, Le, M, et al.: A study of histopathology
and classification on AFP-positive gastric
carcinoma. J Clin Exp Pathol 1999, 15:293–295.
8. Chen X, Ji Z, Lou Y: Clinical characteristics of
α-fetoprotein producing gastric cancer. Mod J
Integr Tradit Chin West Med 2004, 13:2164.
9. Cao Y, Pan L: Analysis of 62 cases of
α-fetoprotein producing gastric cancer. Med J
Communic 2003, 17:514–515.
10. Zheng ZC, Wang SB, Cui XD, Xu HJ, Zhang PF: A
study of the correlation of serum AFP and biologicalbehaviors in gastric cancer. J Pract Oncol 1997,
11:45–47.
11. Hu YQ, Chen HQ, Xu T, Liang ZC, Mao M: Clinical
analysis of gastric carcinoma with high serum level of
α-fetoprotein. Chin Clin Oncol 2007, 12:446–448.
The following data were collected from the 11 articles:
names and addresses of the authors, title, journal, volume,
issue, page range, time range of patients, number of
patients (males and females), median (or average) age
range, site of tumor, diameter of tumor, Borrmann type,
histopathology, differentiation degree, status of vascular
invasion, surgery, stage of disease (TNM), inclusion and
exclusion criteria, values of tumor markers and follow-up.
After evaluation of the 11 studies, the information men-
tioned above was recorded and the results were compared.
A special emphasis was placed on histopathology, diffe-
rentiation degree, vascular invasion status, surgery, disease
stage and outcomes of follow-up. After the evaluation was
finished, a summary form encompassing the 11 studies
and all information concerning indices was completed.
Evaluation of patient characteristics
The 11 studies were conducted in various parts of
China. In these 11 studies, an aggregate total of 4,779
GC patients were enrolled. From among these 4,779 GC
cases, 317 were AFPGCs. The general AFPGC/GC ratio
was 6.63%, which was consistent with the results from
other countries and suggested the annual incidence of
AFPGC was 2% to 3%. Thus, it is necessary to examine
AFP in sera or tissues from patients with GC.
These 317 AFPGC cases included 200 males and 61
females. The gender of the other 56 patients was not
reported in the literature. In the nine studies with data
for age, the age range was 19 to 82 years old. In the 10
studies with the median or average age, the median or
average age was in the range of 55 to 62.2 years old.
Therefore, the gender and age are not the correlation
factors of AFPGC, so that the two studies that did not
report patients’ gender and the one study that did not
report patients’ age were still taken into consideration in
the assessment.
Evaluation of pathological and histological conditions
Information related to tumor locations is available in six
of the studies (studies 2, 5, 6, 7, 8 and 11). In these six
studies, 179 AFPGC cases were included. From among
these cases, the tumors from 93 cases were located in
the antrum (51.9%), 22 were in the body of the stomach
(12.3%), 49 were in the cardia or bottom of the stomach
(27.4%) and 15 were in the whole stomach (8.4%).
Information related to the diameters of tumors is
available in six studies (studies 1, 2, 3, 5, 6 and 10). Be-
cause of the different ways of reporting these data, the
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there were a total of 93 AFPGC cases. Among these
cases, there were 20 cases with the tumor diameters less
than 3 cm (21.5%), and the other 73 cases with tumor
diameters more than 3 cm (78.5%). In studies 1 and 6,
there were totally 53 AFPGC cases. Among these
53 cases, there were 34 with tumor diameters less than
5 cm (64.2%), and the other 19 had tumor diameters
more than 5 cm (35.8%).
Information correlated with Borrmann type was avai-
lable in five studies (studies 1, 2, 3, 5 and 10). In these
five studies, there were 174 AFPGC cases. Among these
cases, there were 77 classified as Borrmann types I and
II (44.3%) and 97 classified as Borrmann types III and IV
(55.7%).
Information related to histopathological type was avail-
able in three studies (studies 1, 3 and 9). In these three
studies, there was an aggregate a total of 112 AFPGC
cases. From among these cases, 76 cases were adenomas
(9 cases of papillary cystadenocarcinoma, 16 cases of
tubular adenocarcinoma, 3 cases of mucinous adenocar-
cinoma and 48 unknown) (67.9%), 15 cases were signet
ring cell carcinoma (13.4%), 7 were medullary carcinoma
(6.2%) and 14 were undifferentiated carcinomas (12.5%).
Information correlated with differentiation degree was
available in five studies (studies 1, 2, 5, 6 and 8). In these
five studies, there was an aggregate total of 106 AFPGC
cases. From among these cases, 19 cases had strong or
moderate differentiation (17.9%) and 87 had poor or no
differentiation (82.1%). Information related to vascular
invasion was available in two studies (studies 1 and 7).
In these two studies, there was an aggregate total of 95
AFPGC cases. From among these cases, 60 had vascular
invasion (63.2%) and 35 did not (36.8%).
Evaluation of clinical stage conditions
Information related to serosal infiltration (T) was avai-
lable in five studies (studies 3 through 6 and study 10).
In these five studies, there was an aggregate total of 77
AFPGC cases. From among these cases, 29 did not have
serosal penetration (T1 or T2) (37.7%) and 48 did (T3 or
T4) (62.3%).
Information correlated with lymph node metastasis
(N) was available in eight studies (studies 1 through 8).
In these eight studies, there was an aggregate total of
203 AFPGC cases. From among these cases, 27 cases
had no lymph node metastasis (N0) (13.3%) and 176 did
(N1 through N3) (86.7%). In three of the eight studies
(studies 2 through 4), the number of metastatic lymph
nodes was available. In these three studies, there was an
aggregate total of 55 AFPGC cases. From among these
cases, 6 did not involve lymph node metastasis (10.9%),
7 had metastasis of 1 to 4 lymph nodes (12.7%) and 42
had metastasis of more than 4 lymph nodes (76.4%).Information associated with liver metastasis was avail-
able in nine studies (studies 1 through 9). In these 9
studies, there was an aggregate total of 265 AFPGC
cases. From among these cases, 144 involved liver me-
tastasis (54.3%) and 121 did not (45.7%).
Information correlated with the disease stages was
available in six studies (studies 1 through 4 and studies
10 and 11). In these 6 studies, there was an aggregate
total of 139 AFPGC cases. From among these cases, 9
cases were at stage I (6.5%), 19 were at stage II (13.7%),
33 were at stage III (23.7%) and 78 were at stage IV
(56.1%).
Evaluation of patient outcomes
Information correlated with median survival time (MST)
was available in two studies (studies 1 and 5). The MSTs
were 35.7 and 18.7 months, respectively, and the overall
MST was 31.1 months. Information correlated with the
1-year, 3-year and 5-year survival rates was available in
4, 4 and 5 studies, respectively. The 1-year survival rate
was in the range of 47.6% to 92.1% (studies 2 through 4
and study 11). The 3-year survival rate was in the range
of 8.9% to 58.3% (studies 2 through 4 and study 11). The
5-year survival rate was in the range of 0% to 49.8%
(studies 1 through 5). The overall 1-year, 3-year and
5-year survival rates were 53.1% (n = 97), 18.7% (n = 97)
and 8.7% (n = 99), respectively.
Evaluation of other parameters
Information correlated with the expression of vascular
endothelial growth factor (VEGF) was available in only
study 2. There was a total of 19 cases with VEGF-
positive expression among these total 21 AFPGC cases
(90.5%). Information correlated with AFP level, CEA
level and hepatitis B virus (HBV) expression, and overall
survival time was not statistically significant.
Evaluation of gender
Information correlated with gender was available in
three studies (studies 1, 2 and 6). In these three studies,
there were aggregate totals of 74 AFPGC cases and 808
non-AFPGC cases. From among these cases, 54 AFPGC
patients and 579 non-AFPGC patients were male (73.0%
vs. 71.7%, respectively), and 20 AFPGC patients and 229
non-AFPGC patients were female (27.0% vs. 28.3%,
respectively).
Evaluation of pathological and histological conditions
Information related to the tumor sites was available in
three studies (studies 2, 5 and 6). These three studies
comprised aggregate totals of 54 AFPGC cases and 483
non-AFPGC cases. From among these cases, 23 were
AFPGC cases and 144 were non-AFPGC cases with
observed tumors in the antrum (42.5% vs. 29.8%,
Table 1 Comparison of clinical traits of α-fetoprotein-producing gastric cancer and non-α-fetoprotein-producing gastric
cancer patientsa
Characteristics AFPGCs, n (%) Non-AFPGCs, n (%) Studies, n (study number)
Gender, N 74 808 3 (1, 2, 6)
Male 54 (73.0) 579 (71.7)
Female 20 (27.0) 229 (28.3)
Tumor site 54 483 3 (2, 5, 6)
Antrum 23 (42.5) 144 (29.8)
Body of stomach 15 (27.8) 156 (32.3)
Cardia or bottom of stomach 15 (27.8) 177 (36.7)
Whole stomach 1 (1.9) 6 (1.2)
Diameter of tumor,b N 83 989 5 (1 to 3, 5, 6)
<3 cm 19 (22.9) 373 (37.7)
>3 cm 64 (77.1) 616 (62.3)
Diameter of tumor,b N 53 567 2 (1, 6)
<5 cm 34 (64.2) 487 (85.9)
>5 cm 19 (35.8) 80 (14.1)
Borrmann type, N 39 442 2 (2, 3)
I or II 16 (41.0) 197 (44.6)
III or IV 23 (59.0) 245 (55.4)
Histopathological type, N 32 436 1 (1)
Papillary cystadenocarcinoma 3 (9.4) 212 (48.6)
Tubular adenocarcinoma 11 (34.3) 45 (10.3)
Mucinous adenocarcinoma 3 (9.4) 94 (21.6)
Signet ring cell carcinoma 6 (18.8) 57 (13.1)
Undifferentiated 9 (28.1) 28 (6.4)
Differentiation degree, N 86 919 4 (1, 2, 5, 6)
Well or moderate 12 (14.0) 290 (31.6)
Poor or none 74 (86.0) 629 (68.4)
Serosal infiltration N 67 614 4 (3 to 6)
T1 or T2 26 (38.8) 285 (46.4)
T3 or T4 41 (61.2) 329 (53.6)
Lymph node metastasis,c N 120 1291 6 (1 to 6)
No 18 (15.0) 492 (38.1)
Yes 102 (85.0) 799 (61.9)
Lymph node metastasis,c N 55 613 3 (2 to 4)
0 6 (10.9) 235 (38.3)
1 - 4 7 (12.7) 212 (34.6)
> 4 42 (76.4) 166 (27.1)
Liver metastasis, N 120 1291 6 (1 to 6)
Yes 68 (56.7) 255 (19.8)
No 52 (43.3) 1,036 (80.2)
Stage, N 87 1049 4 (1 to 4)
I 4 (4.6) 198 (18.9)
II 14 (16.2) 366 (34.9)
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Table 1 Comparison of clinical traits of α-fetoprotein-producing gastric cancer and non-α-fetoprotein-producing gastric
cancer patientsa (Continued)
III 23 (26.4) 325 (31.0)
IV 46 (52.8) 160 (15.2)
VEGF expression, N 21 241 1 (2)
Positive 19 (90.5) 162 (67.2)
aAFPGC, α-fetoprotein-producing gastric cancer; VEGF, vascular endothelial growth factor. bBecause of the different ways of reporting these data, the studies were
evaluated twice. In studies 1 through 3 and study 5, the cut-off diameter is 3 cm. In studies 1 and 6, the cut-off diameter is 5 cm. cIn studies 2 through 4, the
number of metastatic lymph nodes is available. In other studies, the number is not available.
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AFPGC cases with tumors observed in the body of the
stomach (27.8% vs. 32.3%, respectively), 15 AFPGC cases
and 177 non-AFPGC cases had tumors observed in the
cardia or bottom of the stomach (27.8% vs. 36.7%, res-
pectively) and 1 AFPGC and 6 non-AFPGC cases with
tumors were observed in the whole stomach (1.9% vs.
1.2%, respectively).
Information correlated with the tumor diameters was
available in five studies (studies 1 through 3 and studies 5
and 6). Because of the different ways of reporting these
data, the studies were evaluated twice. In studies 1
through 3 and study 5, there were 83 AFPGC cases and
989 non-AFPGC cases. From among these cases, 19 were
AFPGC cases and 373 were non-AFPGC cases with tumor
diameters less than 3 cm (22.9% vs. 37.7%, respectively)
and 64 AFPGC cases and 616 non-AFPGC cases with
tumor diameters larger than 3 cm (77.1% vs. 62.3%,
respectively). In addition, in studies 1 and 6, there were
aggregate totals of 53 AFPGC cases and 567 non-AFPGC
cases. From among these cases, 34 were AFPGC cases
and 487 were non-AFPGC cases with tumor diameters
less than 5 cm (64.2% vs. 85.9%, respectively) and 19
AFPGC cases and 80 non-AFPGC cases with tumor dia-
meters larger than 5 cm (35.8% vs. 14.1%, respectively).
Information related to Borrmann type was available in
two studies (studies 2 and 3). In these two studies, there
were aggregate totals of 39 AFPGC cases and 442 non-
AFPGC cases. From among these cases, there were aggre-
gate totals of 16 AFPGC cases and 197 non-AFPGC cases
belonging to Borrmann types I and II (41.0% vs. 44.6%,
respectively) and 23 AFPGC cases and 245 non-AFPGC
cases belonging to Borrmann types III and IV (59.0% vs.
55.4%, respectively).
Information correlated with histopathological type was
available in one study (study 1). In that study, there were
aggregate totals of 32 AFPGC cases and 436 non-
AFPGC cases. From among these cases, there were
aggregate totals of 3 AFPGC cases and 212 non-AFPGC
cases with papillary cystadenocarcinoma (9.4% vs. 48.6%,
respectively), 11 AFPGC cases and 45 non-AFPGC cases
with tubular adenocarcinoma (34.3% vs. 10.3%, res-
pectively), 3 cases AFPGC cases and 94 non-AFPGC
cases with mucinous adenocarcinoma (9.4% vs. 21.6%,respectively), 6 AFPGC cases and 57 non-AFPGC cases
with signet ring cell carcinoma (18.8% vs. 13.1%, respect-
ively) and 9 AFPGC cases and 28 non-AFPGC cases
with undifferentiated carcinoma (28.1% vs. 6.4%,
respectively).
Information correlated with differentiation degree was
available in four studies (studies 1, 2, 5 and 6). In these
four studies, there were aggregate totals of 86 AFPGC
cases and 919 non-AFPGC cases. From among these
cases, there were 12 AFPGC cases and 290 non-AFPGC
cases with strong or moderate differentiation (14.0% vs.
31.6%, respectively) and 74 AFPGC cases and 629 non-
AFPGC cases with poor or no differentiation (86.0% vs.
68.4%, respectively).
Evaluation of clinical stages
Information correlated with serosal infiltration (T) was
available in four studies (studies 3 through 6). In these
four studies, there were aggregate totals of 67 AFPGC
cases and 614 non-AFPGC cases. From among these
cases, there were aggregate totals of 26 AFPGC cases and
285 non-AFPGC cases without serosal penetration (T1 or
T2) (38.8% vs. 46.4%, respectively) and 41 AFPGC cases
and 329 non-AFPGC cases with serosal penetration
(T3 or T4) (61.2% vs. 53.6%, respectively).
Information correlated with lymph node metastasis (N)
was available in six studies. In those six studies, there were
aggregate totals of 120 AFPGC cases and 1,291 non-
AFPGC cases. From among those cases, there were 18
AFPGC cases and 492 non-AFPGC cases without lymph
node metastasis (N0) (15.0% vs. 38.1%, respectively) and
102 AFPGC cases and 799 non-AFPGC cases with lymph
node metastasis (N1 to N3) (85.0% vs. 61.9%, respectively).
The number of metastatic lymph nodes was available in
three of these six studies (studies 2 through 4). In those
three studies, there were aggregate totals of 55 AFPGC
cases and 613 non-AFPGC cases. From among these
cases, there were aggregate totals of 6 AFPGC cases and
235 non-AFPGC cases without lymph node metastasis
(10.9% vs. 38.3%, respectively), 7 AFPGC cases and 212
non-AFPGC cases with metastasis of 1 to 4 lymph nodes
(12.7% vs. 34.6%, respectively) and 42 AFPGC cases and
166 non-AFPGC cases with metastasis of more than 4
lymph nodes (76.4% vs. 27.1%, respectively).
Table 2 Comparison of survival of α-fetoprotein-producing gastric cancer and non-α-fetoprotein-producing gastric
cancer patients
Survival data AFPGCs, n (%) Non-AFPGCs, n (%) Studies, n (study number)
Case number 12 111 1 (5)
Median survival time, months 18.7 41.3
1-year survival rate, N 37 412 2 (2, 4)
21 (58.0) 377 (91.4)
3-year survival rate, N 37 412 2 (2, 4)
4 (11.3) 248 (60.1)
5-year survival rate, N 49 523 3 (2, 4, 5)
5 (9.4) 164 (31.3)
AFPGC, α-fetoprotein-producing gastric cancer.
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these six studies. In these six studies, there were aggre-
gate totals of 120 AFPGC cases and 1291 non-AFPGC
cases. From among these cases, there were 68 AFPGC
cases and 255 non-AFPGC with liver metastasis (56.7% vs.
19.8%, respectively) and 52 AFPGC cases and 1036 cases
without liver metastasis (43.3% vs. 80.2%, respectively).
Information correlated with disease stages was avail-
able in four studies (studies 1 through 4). In these 4
studies, there were aggregate totals of 87 AFPGC cases
and 1,049 non-AFPGC cases. From among these cases,
there were 4 AFPGC cases and 198 non-AFPGC cases at
stage I (4.6% vs. 18.9%, respectively), 14 AFPGC cases
and 366 non-AFPGC cases at stage II (16.2% vs. 34.9%,
respectively), 23 AFPGC cases and 325 non-AFPGC
cases at stage III (26.4% vs. 31.0%) and 46 AFPGC cases
and 160 non-AFPGC cases at stage IV (52.8% vs. 15.2%,
respectively).
Evaluation of patient outcome
Information correlated with MST was available in one
study (study 5). In that study, there were 12 AFPGC
cases and 111 non-AFPGC cases. The mean MSTs were
18.7 months for the AFPGC group and 41.3 months for
the non-AFPGC group. The 1-year survival rate was
reported in two studies (studies 2 and 4). The overall
1-year aggregated survival rates were 58.0% for AFPGC
groups and 91.4% for the non-AFPGC groups, res-
pectively. The 3-year survival rate was reported in two
studies (studies 2 and 4). The overall aggregated 3-year
survival rates were 11.3% for the AFPGC groups and
60.1% for the non-AFPGC groups, respectively. The
5-year survival rate was reported in three studies (studies
2, 4 and 5). The overall aggregated 5-year survival rates
were 9.4% for the AFPGC groups and 31.3% for the non-
AFPGC groups, respectively.
Evaluation of other parameters
Information associated with VEGF expression was avail-
able in only one study (study 2). In that study, there were19 cases with VEGF-positive expression from among the
21 AFPGC cases and 162 cases with VEGF-positive
expression from among the 241 non-AFPGC cases
(90.5% vs. 67.2%, respectively). Information related to vas-
cular invasion, AFP level, CEA level, HBV expression,
overall survival time and MST was not statistically signifi-
cant. The clinical traits of AFPGC and non-AFPGC are
shown in Table 1, and survival information is given in
Table 2.
We conducted this evaluation to explore the charac-
teristics of AFPGC and to compare AFPGC with non-
AFPGC. We found that patients with AFPGC had larger
tumor size, weaker cell differentiation, worse histopa-
thological type, deeper serosal infiltration, more lymph
node and liver metastases, more advanced stages, shorter
survival time and more VEGF-positive expression than
patients with non-AFPGC. These observations are con-
sistent with the results from other studies of AFPGC.
Overall, we have confirmed that AFPGC is a subtype of
GC that carries a poorer prognosis than non-AFPGC.
A previous report found a 2.5% prevalence of AFPGC in
104 AFPGC patients in China [8], which is less than our re-
sults. The discrepancy might be due to the different
methods used for the measurement of serum AFP level or
to regional or racial differences. From among the 11 studies
we reviewed, some involved the measurement of AFP level
in serum and others measured AFP through immunohisto-
chemical evaluation. We cannot distinguish the difference
because of the incomplete data provided in these publica-
tions. Overall, the objective prevalence requires more re-
peated studies with larger sample sizes.
We found that more than 40% of AFPGC cases deve-
loped in the antrum of the stomach, which suggests the
importance of detecting AFP level in GC at the antrum.
Particularly, liver metastasis is a very important prog-
nostic factor during the control of AFP-positive gastric
cancer because 56.7% of AFPGC patients in our eva-
luation had liver metastasis. Liver metastasis leads to
poor liver function, resulting in intolerance of various
treatment modalities and unsatisfying quality of life.
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AFP level because the tumor exhibits a tendency to
metastasize to the liver, even if the tumor is no deeper
than the submucosa [9-12]. Recurrence of the tumor in
the liver after surgery is a major cause of poor outcomes.
More than 90% of AFPGC cases exhibit high expression of
VEGF, which suggests that VEGF inhibitors can be used for
the treatment of AFPGC. The treatment efficacy using VEGF
inhibitors may be better than that in other subtypes of GC.
It should be noted that increasing AFP level could also be
observed in damaged liver cells from alcoholics, patients with
chronic liver cirrhosis and carriers of the surface antigen of
the hepatitis B virus. Thus, it is important to exclude these
patients from studies to eliminate the selection bias [13].
The molecular or cellular mechanisms resulting in
aggressive clinical behavior and poor prognosis of AFPGC
are still unclear. However, AFPGC is associated with
higher proliferative activity, weaker apoptosis and more
plentiful neovascularization because AFPGC has poor cell
differentiation and positive expression of VEGF [7,14].
According to previous reports, the abnormal expression of
CD10, caudal-type homeodomain transcription factor
CDX. and c-Met may also play critical roles in the occur-
rence, development and aggressiveness of AFPGC [15,16].
We attempted to analyze the statistical differences
between different groups; however, this investigation is
very heterogeneous because of some missing data, so it
is difficult to perform a meta-analysis. However, the pre-
sented data give an impression that the prognosis of
AFPGC is actually poorer than that of non-AFPGC,
which can provide some useful information for clinical
physicians. Although there has been no systematic re-
view or meta-analysis to date, we believe that our eva-
luation can provide an overall review of AFPGC.
Conclusions
AFPGC is a subtype of GC with a high risk of rapid me-
tastasis to the liver. Its aggressive behavior, as well as its
unique clinicopathological features, should be explored
further at the cellular and molecular levels to develop
effective therapies in multiple modes. In this review, we
did not present the therapeutic modalities because of
the lack of standard treatment procedures. Further stu-
dies with larger sample sizes are needed.
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